Drugs / Darovasertib
Darovasertib
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02601378 | Feb 2016 → Jan 2022 | uveal melanoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03947385 | Jun 2019 → Jan 2027 expected | colorectal cancer, cutaneous melanoma, uveal melanoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05907954 | Jul 2023 → Apr 2027 expected | uveal melanoma | IDEAYA Biosciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05187884 | May 2022 → Jan 2025 | ocular melanoma | St Vincent's Hospital, Sydney | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05987332 | Oct 2023 → Jan 2027 expected | uveal melanoma | IDEAYA Biosciences | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07015190 | Jan 2026 → Oct 2030 expected | uveal melanoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darovasertib | “IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma” NCT05987332 ↗ |
| Known as | IDE196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03947385 ↗ |
| Known as | LXS196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02601378 ↗ |
| Known as | NVP-LXS-196 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3982723 ↗ |
| Action | Inhibit | “Protein Kinase C Inhibitor” NCT02601378 ↗ |
| Modality | Small molecule | — CHEMBL3982723 ↗ |
| Route | Oral | “LXS196, an Oral Protein Kinase C Inhibitor” NCT02601378 ↗ |